Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, 210023, China; Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
J Psychiatr Res. 2024 Nov;179:105-116. doi: 10.1016/j.jpsychires.2024.09.005. Epub 2024 Sep 8.
Depressive disorder (DD) ranks among the most prevalent, burdensome, and costly psychiatric conditions globally. It manifests through a range of emotional, cognitive, somatic, and behavioral symptoms. Mesenchymal Stem Cells (MSCs) have garnered significant attention due to their therapeutic potential via immunomodulation in neurological disorders. Our research indicates that MSCs treatment demonstrates a notable effect on a Chronic Unpredictable Mild Stress (CUMS)-induced DD model in mice, surpassing even Fluoxetine in its antidepressant efficacy. MSCs mitigate DD by inhibiting central nervous system inflammation and facilitating the conversion of microglial cells into an Arg1 anti-inflammatory state. The MSCs-derived TGF-β1 is crucial for this Arg1 microglial cell transformation in DD treatment.
抑郁障碍（DD）是全球最普遍、负担最重和最昂贵的精神疾病之一。它表现为一系列情绪、认知、躯体和行为症状。间充质干细胞（MSCs）因其在神经疾病中的免疫调节治疗潜力而受到广泛关注。我们的研究表明，MSCs 治疗在慢性不可预测轻度应激（CUMS）诱导的 DD 模型小鼠中表现出显著效果，甚至超过氟西汀的抗抑郁效果。MSCs 通过抑制中枢神经系统炎症和促进小胶质细胞向 Arg1 抗炎状态转化来缓解 DD。MSCs 衍生的 TGF-β1 对于 DD 治疗中小胶质细胞向 Arg1 的转化至关重要。
